Belmont-Díaz JA, Rodríguez-Zavala JS

Idioma: Español
Referencias bibliográficas: 13
Paginas: 74-79
Archivo PDF: 604.79 Kb.

RESUMEN

La activación de las aldehído deshidrogenasas (ALDHs) tiene un gran potencial terapéutico para múltiples enfermedades humanas. El activador de ALDHs mejor caracterizado es un compuesto sintético denominado Alda-1. En el presente trabajo se muestra el efecto de Alda-1 sobre la cinética de la ALDH2 humana (isoforma mitocondrial), se analiza el tratamiento matemático para obtener los parámetros cinéticos y se discute el significado biológico del efecto de este singular activador.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Koppaka V, Thompson DC, Chen Y, Ellermann M,Nicolaou KC, Juvonen RO, Petersen D, DeitrichRA, Hurley TD & Vasiliou V (2012) AldehydeDehydrogenase Inhibitors: a ComprehensiveReview of the Pharmacology, Mechanism ofAction, Substrate Specificity, and ClinicalApplication. Pharmacol. Rev. 64, 520–539.

2. Lieber CS (2004) Alcoholic fatty liver: Itspathogenesis and mechanism of progression toinflammation and fibrosis. Alcohol 34, 9–19.

3. Fritz KS & Petersen DR (2013) An Overviewof the Chemistry and Biology of ReactiveAldehydes. Free Radic. Biol. Med. 59, 85–91.

4. Voulgaridou GP, Anestopoulos I, Franco R,Panayiotidis MI & Pappa A (2011) DNA damageinduced by endogenous aldehydes: Currentstate of knowledge. Mutat. Res. - Fundam. Mol.Mech. Mutagen. 711, 13–27.

5. Ichihashi K, Osawa T, Toyokuni S & Uchida K(2001) Endogenous formation of protein adductswith carcinogenic aldehydes: Implications foroxidative stress. J. Biol. Chem. 276, 23903–23913.

6. Chen C-H, Ferreira JCB, Gross ER & Mochly-RosenD (2014) Targeting aldehyde dehydrogenase 2:new therapeutic opportunities. Physiol. Rev. 94,1–34.

7. Calleja LF, Yoval-Sánchez B, Hernández-EsquivelL, Gallardo-Pérez JC, Sosa-Garrocho M, Marín-Hernández Á, Jasso-Chávez R, Macías-Silva M& Salud Rodríguez-Zavala J (2021) Activation ofALDH1A1 by omeprazole reduces cell oxidativestress damage. FEBS J. 288, 4064–4080.

8. Yoval-Sánchez B, Calleja LF, de la Luz Hernández-Esquivel M & Rodríguez-Zavala JS (2020)Piperlonguminine a new mitochondrial aldehydedehydrogenase activator protects the heart fromischemia/reperfusion injury. Biochim. Biophys.Acta - Gen. Subj. 1864, 129684.

9. Chen CH, Budas GR, Churchill EN, Disatnik MH,Hurley TD & Mochly-Rosen D (2008) Activationof aldehyde dehydrogenase-2 reduces ischemicdamage to the heart. Science (80-. ). 321,1493–1495.

10. Khan M, Qiao F, Kumar P, Islam SMT, SinghAK, Won J & Singh I (2022) Neuroprotectiveeffects of Alda-1 mitigate spinal cord injury inmice: Involvement of Alda-1-induced ALDH2activation-mediated suppression of reactivealdehyde mechanisms. Neural Regen. Res. 17,185–193.

11. Li M, Xu M, Li J, Chen L, Xu D, Tong Y, Zhang J,Wu H, Kong X & Xia Q (2018) Alda-1 amelioratesliver ischemia-reperfusion injury by activatingaldehyde dehydrogenase 2 and enhancingautophagy in mice. J. Immunol. Res. 2018,9807139.

12. Belmont-Díaz JA, Yoval-Sánchez B, Calleja-Castañeda LF, Pardo Vázquez JP & Rodríguez-Zavala JS (2016) Alda-1 modulates thekinetic properties of mitochondrial aldehydedehydrogenase (ALDH2). FEBS J. 283, 3637–3650.

13. Segel IH. (1993) Enzyme Activation. in EnzymeKinetics. Behavior and Analysis of RapidEquilibrium and Steady-State Enzyme Systems(Segel IH, ed), pp. 227–231. John Wiley & SonsInc., New York, NY.).